SCHEMBL673425

SCHEMBL673425

CCCCCCCCc1ccc(N=C=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.55
TSHR P16473 2/20 0.55
ESR1 P03372 2/20 0.52
ADRA2A P08913 2/20 0.52
ADORA3 P0DMS8 2/20 0.52
TACR2 P21452 2/20 0.52
SLC6A2 P23975 2/20 0.52
SLC6A4 P31645 2/20 0.52
SLC6A3 Q01959 2/20 0.52
HSD17B10 Q99714 2/20 0.52
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
LMNA P02545 1/20 0.52
SHBG P04278 1/20 0.52
TP53 P04637 1/20 0.52
HSPD1 P10809 1/20 0.52
ADRB3 P13945 1/20 0.52
HTR2C P28335 1/20 0.52
HSPE1 P61604 1/20 0.52
HIF1A Q16665 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL991821 1.00 CYP3A4 (0.55) CYP3A4TSHRESR1ADRA2AADORA3
SCHEMBL5885578 1.00 CYP3A4 (0.55) CYP3A4TSHRESR1ADRA2AADORA3
SCHEMBL2488182 1.00 CYP3A4 (0.55) CYP3A4TSHRESR1ADRA2AADORA3
SCHEMBL13725699 1.00 CYP3A4 (0.55) CYP3A4TSHRESR1ADRA2AADORA3
SCHEMBL5884680 1.00 CYP3A4 (0.55) CYP3A4TSHRESR1ADRA2AADORA3
SCHEMBL5885475 1.00 CYP3A4 (0.55) CYP3A4TSHRESR1ADRA2AADORA3
SCHEMBL5885366 1.00 CYP3A4 (0.55) CYP3A4TSHRESR1ADRA2AADORA3
SCHEMBL10400983 1.00 CYP3A4 (0.55) CYP3A4TSHRESR1ADRA2AADORA3
SCHEMBL1403683 0.98 CYP3A4 (0.57) CYP3A4TSHRESR1ADRA2AADORA3
SCHEMBL14565823 0.95 CYP3A4 (0.65) CYP3A4TSHRESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285502-A Free radical self-release antifouling agent containing oxime urethane group and preparation method and application thereof 哈尔滨工程大学 2025-01-10 CN claimed
CN-119285502-A Free radical self-release antifouling agent containing oxime urethane group and preparation method and application thereof 哈尔滨工程大学 2025-01-10 CN disclosed
US-9962398-B2 Sulfonamide compounds for inhibition of metastatic tumor growth WELICHEM BIOTECH INC. (CA) 2018-05-08 US disclosed
EP-2590938-B1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH WELICHEM BIOTECH INC (CA) 2017-06-07 EP disclosed
US-20170007627-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH WELICHEM BIOTECH INC. (CA) 2017-01-12 US disclosed
US-9463171-B2 Sulfonamide compounds for inhibition of metastatic tumor growth WELICHEM BIOTECH INC. (CA) 2016-10-11 US disclosed
US-9029482-B2 Method for preparing polycondensation resin CHEIL INDUSTRIES INC. (KR) 2015-05-12 US disclosed
US-8680282-B2 Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer UNIVERSITY HEALTH NETWORK (CA) 2014-03-25 US disclosed
US-20130190396-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH METASIGNAL THERAPEUTICS INC. (CA) 2013-07-25 US disclosed
US-20130165621-A1 Method for Preparing Polycondensation Resin CHEIL INDUSTRIES INC. (KR) 2013-06-27 US disclosed
US-7022257-B1 Coating composition and floor material coated with said composition SHIN-NAKAMURA CHEMICAL CO., LTD. (JP) 2006-04-04 US disclosed
EP-1144395-B1 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY ALIZYME THERAPEUTICS LTD (GB) 2005-04-20 EP disclosed
US-6656934-B2 Enzyme inhibitor ALIZYME THERAPEUTICS LIMITED (GB) 2003-12-02 US disclosed
US-20030191123-A1 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2003-10-09 US disclosed
US-20030013707-A1 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2003-01-16 US disclosed
US-20020175299-A1 Ultraviolet irradiation apparatus and method of forming cured coating film using the apparatus GEN MAINTENANCE TECHNOLOGY INC. (JP) 2002-11-28 US disclosed
CN-1354747-A 2-amino-4H-3, 1-benzoxazin-4-one derivatives for the treatment of obesity ALIZYME THERAPEUTICS LTD (GB) 2002-06-19 CN disclosed
WO-2000040569-A9 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY ALIZYME THERAPEUTICS LTD (GB) 2002-02-28 WO disclosed
EP-1143977-A1 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY Alizyme Therapeutics Limited (GB) 2001-10-17 EP disclosed
WO-2000040247-A1 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY ALIZYME THERAPEUTICS LIMITED (GB) 2000-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190396-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH HIF1AN, CBX2, HIF1A CYP3A4 4648/4885TSHR 3691/4885ESR1 2795/4885
US-20030191123-A1 2-amino-benzoxazinone derivatives for the treatment of obesity CYP4X1, CYP2B6, BBOX1 CYP3A4 64/4885TSHR 1571/4885ESR1 1982/4885
US-20030013707-A1 2-amino-benzoxazinone derivatives for the treatment of obesity CYP4X1, CYP2B6, BBOX1 CYP3A4 64/4885TSHR 1571/4885ESR1 1982/4885
US-20170007627-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH HIF1AN, CBX2, HIF1A CYP3A4 4648/4885TSHR 3691/4885ESR1 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.